

Genetic Signatures Limited Completes \$14m Capital Raising

Sydney, Australia, 2 September 2016: Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that it has successfully completed an institutional placement to raise \$14 million through the issue of 29.8 million new shares (**Offer**).

The proceeds from the Offer will be used for commercial expansion in Australia, the European Union and USA, obtaining further regulatory approvals for Genetic Signatures' products, continued product development and working capital purposes.

The placement was priced at \$0.47 per share (**Offer Price**), representing a 7.8% discount to the last close price on Tuesday, 30 August 2016 and a 9.6% discount to the 30-day volume weighted average price.

The Offer received strong support from offshore healthcare specialist investors and domestic institutional investors, resulting in the Offer being well oversubscribed at the Offer Price.

Genetic Signatures' Chief Executive Officer, John Melki, said: "We are extremely pleased with the strong level of international and domestic support for the placement. The level of demand from quality institutional investors provides strong validation of the Genetic Signatures technology. The funds raised from this placement will enable Genetic Signatures to continue commercial expansion and accelerate our global growth strategy. The demand from both existing and new investors reflects the strong underlying revenue growth over the past two years and our future growth prospects".

The placement will be completed in two tranches:

- The first tranche of the new shares, being 10.9 million shares and raising \$5.1 million, will be issued on Thursday, 8 September 2016 under Genetic Signature's capacity pursuant to ASX Listing Rule 7.1.
- The issue of the second tranche of the new shares, being 18.9 million shares and raising \$8.9 million, is conditional on shareholder approval. Genetic Signatures will be convening a meeting of shareholders in early October 2016 to seek this approval.

The shares to be issued under both tranches of the placement are fully paid ordinary shares and will rank equally with existing shares in Genetic Signatures from their issue.

Bell Potter Securities Limited acted as Lead Manager to the Capital Raising.

Share Purchase Plan

In conjunction with the placement, a share purchase plan will be offered to eligible shareholders in Australia and New Zealand (**SPP**). Under the SPP, holders of existing shares in Genetic Signatures on the share register as at 7.00pm (Sydney time) on the

record date of Thursday, 1 September 2016 and who are eligible shareholders in Australia or New Zealand will be invited to subscribe for up to \$15,000 of new fully paid ordinary shares in Genetic Signatures per eligible shareholder. The SPP will be capped at \$1 million.

Participation in the SPP will be optional. Further information in relation to the SPP, including the SPP terms and conditions, will be outlined in a separate SPP Booklet which will be dispatched to eligible shareholders.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, *3Base*[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx *3Base*[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.